Stay updated on Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new revision entry (v3.5.3) has been added to the Record History. The previous revision (v3.5.2) has been removed.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedRevision tag updated to v3.5.2 and the v3.5.0 revision was removed.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed from the Record History.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision: v3.4.3 has been added and Revision: v3.4.2 has been removed from the history.SummaryDifference0.1%

- Check93 days agoChange DetectedA new site revision (v3.4.2) was added and a prior funding notice (v3.4.1) removed; these administrative changes do not affect the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check100 days agoChange DetectedA new government funding notice about the NIH Clinical Center operating status has been added. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.6%

Stay in the know with updates to Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.